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Abstract
The stability of various aggregates in the form of lipid bilayer vesicles was tested by three different methods before and after crossing
different semi-permeable barriers. First, polymer membranes with pores significantly smaller than the average aggregate diameter were used
as the skin barrier model; dynamic light scattering was employed to monitor vesicle size changes after barrier passage for several lipid
mixtures with different bilayer elasticities. This revealed that vesicles must adapt their size and/or shape, dependent on bilayer stability and
elasto-mechanics, to overcome an otherwise confining pore. For the mixed lipid aggregates with highly flexible bilayers (TransfersomesR),
the change is transient and only involves vesicle shape and volume adaptation. The constancy of ultradeformable vesicle size before and after
pores penetration proves this. This is remarkable in light of the very strong aggregate deformation during an enforced barrier passage. Simple
phosphatidylcholine vesicles, with less flexible bilayers, lack such capability and stability. Conventional liposomes are therefore fractured
during transport through a semi-permeable barrier; as reported by other researchers, liposomes are fragmented to the size of a narrow pore if
sufficient pressure is applied across the barrier; otherwise, liposomes clog the pores. The precise outcome depends on trans-barrier flux and/or
on relative vesicle vs. pore size. Lipid vesicles applied on the skin behave accordingly. Mixed lipid vesicles penetrate the skin if they are
sufficiently deformable. If this is the case, they cross inter-cellular constrictions in the organ without significant composition or size
modification. To prove this, we labelled vesicles with two different fluorescent markers and applied the suspension on intact murine skin
without occlusion. The confocal laser scanning microscopy (CLSM) of the skin then revealed a practically indistinguishable distribution of
both labels in the stratum corneum, corroborating the first assumption. To confirm the second postulate, we compared vesicle size in the
starting suspension and in the blood after non-invasive transcutaneous aggregate delivery. Size exclusion chromatograms of sera from the
mice that received ultradeformable vesicles on the skin were undistinguishable from the results measured with the original vesicle
suspension. Taken together, the results support our previous postulate that ultradeformable vesicles penetrate the skin intact, that is, without
permanent disintegration. D 2002 Published by Elsevier Science B.V.
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1. Introduction
First description of epicutaneous application of liposomes
is more than 20 years old [1,2]. Since then, close to a thou-
sand papers have been published on the use of vesicles com-
prising non-ionic surfactants [3,4], synthetic or chemically
modified lipids, plant lipids [5,6] or skin lipids [7,8], but also
lipid–surfactant combinations [9] on the skin. In some
studies, skin permeation enhancers were included [1,2]; in
other cases, additional gadgets, such as iontophoresors [10],
were employed to improve the efficacy of transdermal
delivery of lipid vesicles.
Phospholipid vesicle suspensions (liposomes) are con-
tained in five marketed topical therapeutics [11] and at least
nominally in countless cosmetic formulations [12]. This is a
remarkably optimistic practice in light of the huge discrep-
ancy between a typical liposome size and the width of the
natural passage through the skin: even small unilamellar
liposomes are rarely smaller than 50 nm [13] unless they are
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unreasonably (e.g. ultrasonically) stressed, and/or supple-
mented with surfactants or degradation products. In contrast,
pores in the skin are normally 0.3 nm narrow [14] and can
be opened without major skin damage merely to 20–40 nm
at most [14,15]. It is therefore difficult to contemplate how
an entire liposome could cross the skin and participate in its
entirety in transdermal transport.
Many researchers consequently believe that phospholipids
administered on the skin as aggregates first disintegrate and
then diffuse through the barrier in the form of small fragments
or lipid monomers [16–18]; this probably happens to lipid
aggregates below the skin surface. At the skin surface, simple
phospholipid vesicles were reported to break down or to fuse
[16,19,20]. Liposomes made from sufficiently hydrophilic
lipids then may promote material diffusion through the
barrier by increasing the skin hydration [21].
Most lipid vesicles are typically retained on or break in a
semi-permeable barrier with openings significantly smaller
than the average vesicle diameter; pushing lipid suspension
through the cylindrical pores in a polycarbonate membrane
is therefore popular for downsizing conventional liposomes.
The method was introduced by the group of the late D.
Papahadjopoulos [22] and is now often used for manufac-
turing liposomes as drug carriers [23–27].
Extrusion of a lipid suspension through 100 nm pores
yields vesicles of approximately (140F 40) nm diameter
[23]; wider or narrower pores typically yield correspond-
ingly greater or smaller vesicle/pore size ratios [24,28].
Final vesicle size normally falls in the range rpore 1g1.5
rpore [28]. Narrower pores yield higher relative vesicle
diameters in the range and vice versa. Repeated extrusion
also reduces the number of lipid lamellae per vesicle [25]
and brings the final vesicle size closer to the employed pore
diameter [28].
Two essential requirements must be fulfilled for a suc-
cessful extrusion of conventional liposomes through a
microporous barrier: sufficient lipid bilayer fluidity [26]
and the use of extrusion pressure greater than certain,
lipid-dependent lower limit [27]. This limit increases line-
arly with the inverse pore size, as suggested by Young’s
equation [27]. However, pore sizes around or below 30 nm
require exceptionally high pressures in excess of 2 MPa
[27]. They also yield anomalously stressed, and relatively
large, final vesicles.
The question of liposome passage through the skin is
closely related, but not identical, to the problem of vesicle
transport through artificial barriers. For example, with the
experience gained in liposomes extrusion studies, one
cannot explain why small lipid aggregates or solubilised
lipids fail to permeate through the skin better than plain
vesicles. The fact that mixed lipid vesicles with a highly
flexible/fluid membranes are better skin penetrants than the
much smaller mixed lipid micelles [15,29,30] also awaits
generally accepted explanation.
We advocate a differentiated concept of lipid aggregate
transport through the skin. We agree that simple liposomes
do not overcome the barrier intact. We argue, however, that
complex aggregates with a more flexible membrane, so-
called TransfersomesR1 [31,15], can cross the skin without
irreversible disruption. This is due mainly to the fact that
such complex aggregates are at least one order of magnitude
more elastic, and thus more deformable, than simple lipid
liposomes.
To interpret the motion of suitably designed, ultrade-
formable vesicles across the stratum corneum and other less
complex barriers, we introduced a self-consistent theoretical
model [31,32]. This focuses on aggregate deformability and
on the existence of an aggregate independent trans-barrier
gradient are the two most important factors for successful
passage through a semi-permeable barrier [31]. The most
obvious natural transdermal gradient originates from water
activity difference across the stratum corneum [33]. This
gradient acts simultaneously on all vesicle ingredients.
Transdermal hydration difference therefore creates a very
strong force acting on the skin via vesicles. This enforces
widening of the weakest intercellular junctions in the barrier
and creates 20–30-nm-wide transcutaneous channels [34].
The channels allow sufficiently deformed, slimed lipid
vesicles to cross the skin along the said hydration gradient.
Spontaneous motion of the highly deformed, hydrophilic
entities through the skin barrier is consequently based on
barrier penetration rather than on trans-barrier permeation.2
It is therefore inappropriate to apply the rules of diffusion to
vesicle transport across the skin!
To date, TransfersomesR were used to deliver numerous
small chemical entities [30,35] and relatively large thera-
peutics [11,36], but also proteins [37,38] across the skin.
This was done in preclinical experiments using mice, rats,
and pigs as test animals, and also in phase I and phase II
clinical studies. A total of 10 clinical investigations were
successfully completed to date. The ability of Trans-
fersomesR to deliver drugs across the skin is therefore
well-documented and widely accepted. It could not be
clarified, though, whether ultradeformable vesicles can
overcome the skin barrier without fragmentation, that is,
physically intact.
In this publication, we addressed the problem of exog-
enous lipid vesicle detection by combining the results of
three pertinent experimental techniques. For this purpose,
we first used the dynamic light scattering on vesicle
suspension; this demonstrated that the passage of large
ultradeformable vesicles through a nanoporous membrane
can, but need not, be completely non-destructive. Sec-
ondly, we studied the transport of similar fluorescently
labelled vesicles through the stratum corneum by means of
the confocal laser scanning microscopy (CLSM). This
1 TransfersomeR is a trademark of IDEA AG.
2 In the context of this work, we use the word ‘permeation’ to describe
a diffusive trans-barrier flow of individual molecules and the word
‘penetration’ to outline a concentration-independent motion of aggregates
through nanoporous barriers.
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revealed that various labels co-penetrate into murine skin,
we thus confirmed indirectly the maintenance of Trans-
fersomeR composition during the process. Last but not
least, we recovered labelled aggregates from the systemic
blood circulation of the mice that were treated epicuta-
neously with TransfersomesR. Size-exclusion chromatog-
raphy then allowed us to conclude that the recovered
vesicle size is indistinguishable from the size in original
suspension. All data taken together provide a rather com-
pelling evidence for vesicle integrity during and after
crossing a nanoporous barrier, confirming our initial as-
sumption.
2. Materials and methods
2.1. Lipid suspensions
Lipid suspensions were prepared by mixing ingredients
in an organic solvent (CHCl3/CH3OH 1:1 v/v). The solution
was deposited on walls of a glass vessel and dried under
vacuum (V 10 Pa; z 12 h). The resulting thin lipid film was
hydrated with a buffer (pH = 7.2) to create a suspension (10
wt.% total lipid), which was homogenized further by son-
ication (titanium micro-tip, Heat Systems W 380, USA, 30
min, 4 jC). Alternatively, we used a sequential—and in
some cases repeated—filtration through a nanoporous filter
[24] of the appropriate size (i.e., 400, 200, 100, 80 nm) to
the same effect. Vesicle size was measured at different
stages by the dynamic light scattering (ALV-5000 correlator,
ALV-Laser Vertriebsgesellschaft, Langen, Germany; 90j)
under standard conditions (21 jC; 0.2 wt.% total lipid). The
final value was typically 150F 30 nm, unless stated other-
wise.
For microscopy and size-exclusion chromatography,
TransfersomesR were co-labelled with 0.2 mol% to 1.5
mol% rhodamine-DHPE (Lissaminek rhodamine B 1,2-
dihexadecanoyl-sn-glycero-3-phosphoethanolamine, trie-
thylammonium salt; Ex/Em: 560/581), Texas Red-DHPE
(Texas Redk 1,2-dihexadecanoyl-sn-glycero-3-phosphoe-
thanolamine, triethylammonium salt; Ex/Em: 583/601) or
with fluorescein-DHPE (N-(fluorescein-5-thiocarbamoyl-
1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine,
triethylammonium salt; Ex/Em: 496/519), all from Molec-
ular Probes, Eugene, OR, USA). Characteristic wave-
lengths were sufficiently different to allow adequate
differentiation between the used labels. To minimise the
danger of false-positive observations, both labels were
chosen to have a molecular weight significantly higher
(1183 for Fl-PE and 1334 for Rh-PE) than the molecular
weight cut-off for the corresponding monomer diffusion
across the skin [39].
The labels were mixed with the lipids in an organic
solvent. Label co-incorporation into lipid bilayers was
essentially quantitative (see Fig. 1 for illustration) due to
the covalent fluorophore attachment to vesicle bilayers via a
hydrophobic anchor. In spite of this, one would expect to
detect bilayer composition changes, as reflected in fluores-
cence intensity changes, in case of differential label parti-
tioning into the surrounding. Such re-partitioning is not
unlikely after vesicle fragmentation, taken that the two
fluorophores have distinct chemical nature, polarity, size,
and charge. The latter, which is pH sensitive for Fl-PE in the
skin relevant range (pKf 6.2) is particularly likely to cause
said fluorescence deviations.
To obtain deformable vesicles, we increased lipid bilayer
flexibility by adding suitable membrane softening agents
into suspension. ‘Type C’ TransfersomesR were formed
from 89 wt.% phosphatidylcholine (ex soya, 98% pure;
Nattermann Phospholipids, Cologne, Germany) and 11
wt.% sodium cholate (p.a.; Merck, Darmstadt, Germany);
bio-compatible non-ionic surfactants were used in an appro-
priate relative concentration to produce the ‘type T’ suspen-
sions.
2.2. Vesicle transport through an artificial membrane
A nanoporous barrier was used to simulate the skin
barrier. It was chosen to have a high density of constant
size pores and was placed in a custom-made device, similar
to the commercially available stainless steel pressure filter
holders (Sartorius, Go¨ttingen, Germany). This allowed
reproducible measurements of the trans-barrier flow that
was driven by an external hydrostatic pressure. Typically, up
to 18 ml of the test suspension were pushed through a
barrier with pores of 20 nm diameter under the pressure of
up to 1 MPa. Only occasionally larger pore sizes (up to 50
nm) were used. The resulting flux, f, was monitored gravi-
metrically by a remotely controlled analytic balance (Sartor-
ius). Vesicle radius, rv, before and after barrier passage was
measured by the dynamic light scattering (ALV, Langen,
Germany).
2.3. Animal experiments
Nude mice (balb/c, nu/nu; age 8–12 weeks) were kept
under standard laboratory conditions (three to five per
suspending cage; standard diet; water, ad libitum; 12 h
light/dark regime). The test suspensions (10–25 Al) were
administered to a standardized area on the upper back under
mild general anaesthesia (ketamin/xylazin mixture). Ani-
Fig. 1. Schematic representation of a lipid bilayer labelled with two
different lipophilic fluorescent dies (Rh-PE, Fl-PE).
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mals were kept on a heating pad during the sedation period
(30–45 min) and were transferred into cages (one animal/
cage) after recovery.
Excess water from the test suspension typically evapo-
rated in approximately 30 min; a macroscopically dry lipid
film, believed to contain highly concentrated vesicles
suspension, was left behind. Eight to twelve hours after
epicutaneous administration of lipid vesicles (for chromato-
graphic or CLSM experiments, respectively) the study
animals were killed by heart puncture. The residual sus-
pension was removed from the skin with a cotton swab.
The treated skin was then separated from the underlying
tissue. Careful excision yielded 0.5–1 cm2 samples that
were used for microscopic examination (see Ref. [34] for
details).
2.4. Confocal laser scanning microscopy (CLSM)
The LSM 410 invert confocal microscope (Zeiss, Jena,
Germany) with high numeric aperture lenses (Plan-Neo-
fluar oil immersion lenses: 40/1.3, 63/1.4, 100/1.3) and a
minimised pinhole size (V 10% of maximum) was used
for the image acquisition at a maximum pixel resolution
(1024 1024) (more detailed information is given in Ref.
[34]). The 488 nm and 543 nm laser lines were used to
excite fluorescein and rhodamine labels, respectively. (The
focal depth is a function of pinhole size and of the
excitation light wavelength. Pinhole size was therefore
optimised separately for each wavelength, and the focal
depth consequently differed slightly for each label. A
focal depth-based correction would probably have im-
proved probe co-localisation but would also have been
impractical).
Images (320 320 Am2) were taken consecutively with
the optimised dichroitic beam splitters and filters to mini-
mise channel cross-talk. All images were acquired with
identical settings. The photomultiplier gain/sensitivity/con-
trast was adjusted to give a slightly over-modulated signal
scaling in the fast scan mode. Frame averaging resulted in
gray scale images with an optimised final dynamic range.
All images were processed with the software packages AVS
5.1 (Advanced Visualizations System Inc., Waltham, MA,
USA), IDL 3.9 (Research Systems Inc., Boulder, CO, USA)
and Origin 5.0 (Microcal, Northhampton, MA, USA), which
were also used for the calculation of the two-dimensional
correlation functions.
2.5. Size exclusion chromatography
The HPLC system consisted of a quaternary pump P4000,
autosampler AS3500, and a fluorescence detector FL 3000
(all from Thermoseparation Products, Hanau, Germany). A
refractive index detector (ERC 7512, ERC Inc., Tokyo,
Japan) was used as well. The mobile phase (pH = 6.8) con-
tained 0.5 M Na2HPO4/NaH2PO4, 0.15 M NaCl and 0.1 mM
NaN3.
The BioRad SEC columns SEC4000 and SEC6000 were
used in a series to increase resolution. For quality controls, a
series of globular proteins (GFC standard 151-1901, Bio-
Rad, Mu¨nchen, Germany) was used, and a suspension of
well-defined, monodisperse vesicles with the known diam-
eter was measured with the dynamic light scattering. For
each data point determination, 5–10 Al of undiluted serum
were injected and analysed using a flow rate of 0.5–1.5 ml
min  1 at 30 jC.
3. Results
The aim of our study was to investigate the passage of
ultradeformable vesicles through nanoporous barriers, mim-
icking or obtained from the skin, with regard to aggregate
fragmentation or disintegration.
Previous studies [15] have shown that bilayer elasticity is
governing factor for vesicle transport through the skin. The
other factor is the force/pressure exerted on the skin by an
aggregate. If this force is strong enough, we postulated it
can open channels in the barrier up to the size of the
deformed vesicle. The process depends on vesicle size
before and in the pore, and therefore on vesicle integrity
during barrier crossing.
TransfersomesR differ from more conventional lipid
aggregates in several respects. The most important is the
extremely high and stress-dependent adaptability of such
mixed lipid aggregates. Said aggregates are thus ultrade-
formable and can squeeze themselves between the cells in
the stratum corneum, despite the large average vesicle size.
The provisos are high membrane elasticity and permeability,
sufficient vesicle stability, and a large enough trans-barrier
water activity gradient. (The central role of hydrotaxis in
transcutaneous transport explains why the skin occlusion
normally lowers the rate of transcutaneous lipid vesicle
transfer despite the fact that it increases the rate of concen-
tration-driven molecular permeation across the skin).
Vesicle deformation in a confining pore can be ex-
pressed in terms of an elongation factor. This is obtained
by dividing the length of a spherically-caped, cylindrically
deformed vesicle in a pore with the diameter of an
assumedly spherical vesicle outside the pore. The purely
geometrical result is given in relative units in Fig. 2. This
shows that a vesicle three times greater than the pore
diameter has to grow by more than this factor in length
inside a pore. This creates a rather unfavourable thickness–
length ratio.
An elongation ratio of 3.3:1 would be required for a
small, unilamellar 60 nm vesicle if this aggregate were to
enter a 20 nm pore in the skin; for a 120 nm vesicle the
factor is 6.6:1. Obviously, deformations of this magnitude
are not achievable with pure phosphatidylcholine lipo-
somes: such vesicles are fractured only with great difficulty
to the size of 40 nm [40] and typically have a diameter
greater than 60 nm [24] or greater than 100 nm [41].
G. Cevc et al. / Biochimica et Biophysica Acta 1564 (2002) 21–3024
The energy cost for vesicle elongation in a pore must be
paid by an external potential that drives vesicles into its
constriction; the trans-barrier water activity gradient, known
to exist in the outermost skin region, is normally responsible
for this.
3.1. Penetration of an artificial membrane
In order to study in detail the transport of vesicles through
the skin-mimicking, semi-permeable barrier, we developed
an in vitro model. This model relies on measuring the flux
( f ) of vesicle suspension across a nanoporous barrier as a
function of trans-barrier pressure gradient [15,42].
When exposed to a driving pressure around 1 MPa,
ultradeformable vesicles cross pores that are much smaller
than the average vesicle diameter nearly as rapidly as a
buffer of comparable viscosity. This implies that their lipid
bilayer adapts to the stress-induced vesicle deformation. We
described this in greater detail in previous publications
[15,31,36]. This notwithstanding, it is also worthwhile to
investigate whether or not the mixed lipid vesicles with a
highly flexible membrane can penetrate a nanoporous bar-
rier above the transport-enabling pressure limit without
getting broken down. To check for this, we compared the
average aggregate size before and after pore passage at
various flow rates (see Fig. 3).
The high adaptability of certain vesicles allow such
aggregate to maintain sizes much larger than the pore
diameter even after trans-barrier transport. This is tanta-
mount to saying that the consumed energy of a pore cross-
ing is used mainly for reversible vesicle deformation and
friction and not for major vesicle size diminution. In
contrast, liposomes essentially take the size of pores, within
experimental uncertainty limits, unless they approach a
lower size limit of approximately 60 nm.
The ultradeformable mixed lipid vesicles were found to
maintain their size during extrusion through a range of
pores, including very narrow ones; Fig. 4 illustrates this.
Fig. 3. Average final vesicle size relative to pore size as a function of
suspension flux across a barrier. Two unrelated formulations (type C and T)
give qualitatively similar results (bullets), distinctly different from those
pertaining to liposomes (open circles, data from Ref. [27]. The flux is
normalised relative to the transcutaneous flow of material measured in
separate experiments. Grey zone gives an estimate for uncertainty limit of
liposome and pore size, based on experience.
Fig. 4. Normalised vesicle size relatively to and as a function of pore
diameter after the pressure-driven suspension transport through a semi-
permeable barrier. Full, large symbols give results of measurements with
ultradeformable vesicles, TransfersomesR; dots give the results extrapo-
lated to small flux as shown in Fig. 3. Open symbols present the results for
liposomes from Ref. [24]. Grey zone is defined in Fig. 3. Errors that do not
show up are smaller than symbols.
Fig. 2. Normalised vesicle elongation relative to original spherical vesicle
size (rves) as a function of the pore radius (rpore) in a semi-permeable barrier
crossed by a vesicle. To the left of the vertical dashed line, vesicle volume
reduction is a must.
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The starting to final vesicle size ratio in the range tested is
therefore close to one in all cases. Extrapolation into the low
flux/pressure region (as explained for Fig. 3) even gives:
rves/rves,0 = 1F 0.05 (see inset in Fig. 4). Extending the
experimental range on the high end is problematic. This is
due to the difficulty of preparing unilamellar vesicles with a
starting size of two or more times greater than the pore
diameter, which is the assay’s lower sensitivity limit. This
also explains why the rves/rpore value in our data set
approaches this lower limit.
3.2. Murine skin penetration
The resistance of ultradeformable vesicles to fragmenta-
tion in murine skin was studied in vivo using dual label
fluorescence. The CLSM was used to monitor fluorophore
distribution. The success of rhodamine-PE/fluorescein-PE
co-labelled vesicle transport into the skin was deduced from
the fluorescence intensity distribution profiles in the organ.
Fig. 5. One-dimensional correlation factor for the intradermal fluorescence
of rhodamine-phosphatidylethanolamine (Rh-PE) and of fluorescein-
phosphatidylethanolamine (Fl-PE) as a function of depth in murine skin
treated with labelled ultradeformable vesicles, TransfersomesR, without
occlusion.
Fig. 6. Two-dimensional correlation analysis (Fourier representation) of lateral fluorescence intensity distribution in the skin treated non-occlusively with
ultradeformable vesicles, TransfersomesR, co-labelled with rhodamine-phosphatidylethanolamine (Rh-PE) and fluorescein-phosphatidylethanolamine (Fl-PE).
The central peak is indicative of similar spatial distributions of the two labels in the skin, and thus indirectly confirms chemical vesicle integrity during the skin
passage. The size of each field is 320 320 Am2.
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The resolution limit of CLSM pictures is a combination
of several factors: the different depth of focal planes
associated with different analysed wavelengths, causing
chromatic aberration; the relative distortion of pictures
(e.g., due to astigmatism); and the focal resolution-limit of
each individual microscopic picture. We considered all these
factors when comparing the confocal micrographs to deduce
the actual distribution of individual labels in the skin at
different depths. Both labels were then concluded to have a
qualitatively similar penetration characteristic in the skin
(data not shown).
Quantitative comparison of fluorescence intensities is not
trivial for a variety of reasons, such as photo-bleaching and
quenching. The latter can reflect variations in the micro-
environment of a fluorescent probe; changes in the local salt
or oxygen concentration; pH differences, to which the used
dye is sensitive, etc. In order to compare quantitatively the
micrographs pertaining to the different used labels, we first
analysed fluorescence data with the conventional correlation
analysis. This yielded correlation coefficients that reflected
the similarity of each optical cross-section for the chosen
label. Minor differences in peak intensity notwithstanding,
the normalised profiles were very similar and well correlated
(see Fig. 5). Specifically, in the stratum corneum, where the
vesicles are exposed to the greatest stress, the correlation
coefficient for both labels was above 0.95. Lowest values
were measured deep in the viable epidermis, however.
To eliminate further the bias from the label-specific
intensity variations, we exploited spatial information in the
individual label distributions in each optical cross-section.
For this purpose, we included translational shifts of the
micrographs measured with individual labels at one depth
against each other:
CorrelationðrÞi ¼< IFlPEi ; IðrÞRhPEi > ,
I(r) is the shift of micrograph I by a lateral vector r. This
allowed direct comparison of the proximal areas in the skin.
We expected to get hints about individual label demixing
and repartitioning in the skin after vesicles disintegration, if
any occurred. Less quantitatively, we interpreted the central
peak in the resulting two-dimensional correlation maps as a
measure of the similarity in the spatial distribution of both
inspected labels, according to the theory of Fourier analysis.
Results of our CLSM data analysis are given in Fig. 6.
They confirm the basic similarity of the two-dimensional
correlation function for both fluorescent labels to the depth
of 15 Am in the skin; this is 5–8 Am below the stratum
corneum/viable epidermis boundary in murine skin. More
details on the skin penetration profiles of fluorescent ultra-
deformable vesicles are given in Ref. [34].
The high level of correlation in the spatial distribution of
different investigated labels in the skin barrier is not what
would be expected if vesicles fell apart or if lipid aggregates
exchanged their material extensively with the cells in the
skin. At the depth of approx. 6 Am, where the skin perme-
ability barrier is highest [34], one would expect maximum
stress on vesicles penetrating intercellular contacts. If ultra-
deformable vesicles in this region underwent complete
disintegration, or were engaged in strong fragmentation,
label demixing should be detected; the central correlation
peak should then diminish, or even disappear. As the peak is
preserved throughout the stratum corneum, this is an indi-
cation of the vesicle’s resistance to said changes.
To substantiate the abovementioned conclusion, we exa-
mined the size of transdermally delivered TransfersomesR
in the serum.
The elution profile of the sera collected from the mice
treated with ultradeformable vesicles on the skin showed
two main peaks. The first (fraction 6) was not observed with
the control sera from the untreated mice; similar elution
peak was seen in the chromatogram pertaining to the
starting vesicle suspension, however. The second peak
(fraction 13) was found in the blood of untreated and treated
mice alike, but not with the original vesicle suspension. This
maximum therefore corresponds to the fluorescent serum
components.
It stands to reason that the first peak stems from the
vesicles that have crossed the skin intact, and have sub-
sequently found their way through lymphatic drainage into
systemic blood circulation. The magnitude of such peaks
can vary and depends on factors other than the average
vesicle size. Averaging several chromatograms would there-
fore result in meaningless standard deviations. In Fig. 7,
consequently, only the results of one experiment are given.
Confirmatory experiments were done with the fluores-
cence activated cell sorter. These experiments also revealed
no difference between the sera spiked with the original
vesicle suspension and the sera collected from the mice that
Fig. 7. Elution (size distribution) profile of the serum from untreated mice
(dots) and from the mice treated with ultradeformable, fluorescently
labelled TransfersomesR on non-occluded skin (bullets) for 8 h. The result
of control measurement with the starting suspension is shown as open,
small circles.
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received ultradeformable vesicles on the skin (data not
shown).
4. Discussion
To date, no general concept has been agreed upon to
explain the fate of lipid vesicles on and in the skin. Different
researchers have studied the fate of epicutaneously applied
vesicles with electron microscopy [18], perturbed g,g angu-
lar correlation spectroscopy (PAC) [17], fluorescence spec-
troscopy [20], and other experimental methods [16].
Generally, only few [43,44], if any [18], vesicles were
found in the skin. This was explained with the lack of
vesicle transport into the organ, in agreement with our own
results obtained with conventional lipid vesicles.
It is therefore clear that conventional vesicles are con-
fined to the skin surface, with exception of pilosebaceous
units [34,45] and rare skin packing imperfections (see Ref.
[34] and unpublished data). An alternative explanation
would be the lack of experimental sensitivity.
With the labelled ultradeformable vesicles we uncovered
the existence of hydrophilic pathways in the skin [34].
These are typically located between cell envelopes and
intercellular lipids and can be widened into ‘virtual chan-
nels.’ The resulting transcutaneous pathways can accommo-
date specially designed, highly deformable, and hydrophilic
lipid aggregates. The proviso is that said aggregates are
sensitive enough to the transdermal hydration gradient, so as
to open channels in the skin barrier, and simultaneously are
deformable enough to fit into channel openings. Obviously,
even the most deformable vesicles cannot enter a signifi-
cantly narrower pore without volume change; if the expan-
sivity/compressibility of a vesicle bilayer is too small, pore
entry is impossible.
Any vesicle therefore must lose some of its content
during deformation in a pore (see Fig. 2). This compensates
for the volume difference between a sphere and an ellipsoid,
or any other non-spherical shape adapted to the pore size. In
practice, such a volume exchange does not negatively affect
trans-barrier transport of the vesicle associated agents. This
holds true as long as volume exchange takes place inside a
pore as the confined surrounding and the limited volume of
extravesicular space prevent an escape of released content.
Transient vesicle poration inside a narrow channel even
offers an opportunity for additional loading of vesicle
interior with water-soluble substances; this is likely to
happen inside a transcutaneous channel during the hydro-
taxis-driven transport. Vesicle post-loading is then driven by
the outside–inside directed concentration gradient, caused
by water evaporation from the skin surface.
Our experiments revealed that the final, relative vesicle
size is a function of transport rate: with increasing trans-
barrier flux the relative average aggregate size typically
decreases, Drvesu rves,start rves,endz 0. The process is
quasi-exponential (see the curves in Fig. 3) with an essen-
tially constant, and vesicle composition-independent, nor-
malised decrement:
Drves,normðf Þuðrves,finalðf Þ  rporeÞ=ðrves,star  rporeÞ~logf :
Vesicles fragmentation is thus appreciable only if flux is
high. Little or no vesicle size diminution occurs at low
barrier passage rate.
The results given in Fig. 3 show that high vesicles
deformability allows even relatively large aggregates to
maintain their average size during crossing a pore. Higher
flow through a pore dissipates more energy, however. Work
is now partly consumed to overcome viscous friction before
and in the pore and partly for vesicle diminution. The fact
that the change in diameter for vesicles of different compo-
sition and size is similar on a relative rather than on an
absolute scale (cf. the last empirical mathematical relation
given above) is per se revealing. It suggests that vesicles are
fragmented in the turbulent stream of a fluid before a pore
rather than in the pore proper.
Under all experimental conditions used in this work, the
ultradeformable vesicles remained appreciably larger than
the nominal pore size: rv,final/rpore f 3. . .6. This is appreci-
able, taken that the tested pore width (20 nm) was two times
smaller than the smallest reasonable diameter of a conven-
tional phosphatidylcholine vesicle (45 nm) and 7–12 times
smaller than the starting TransfersomeR diameter. Ultra-
deformable vesicles thus must have survived correspond-
ingly strong elongation in a pore (cf. Fig. 2). This must have
involved at least local bilayer poration at vesicle end(s),
allowing rapid expulsion of the excess water volumes. This
reflects the fact that a sphere has a greater volume/surface
ratio than a cylindrical vesicle. Deformed vesicles inside a
pore therefore must have at least transiently open end(s) and
can easily be mistaken for endogenous lipid multilamellae.
One should not expect to find the customary spherical,
closed vesicles in very narrow pores.
Extensive vesicle elongation in the vortex in front of a
pore is more difficult to sustain than in the confined space of
a pore. Pre-barrier vesicle elongation is thus prone to lead to
progressive vesicle fragmentation with increasing trans-
barrier flux and increasing turbulence in the stream of the
pore-approaching fluid. Flux-effect is illustrated in Fig. 3
and corroborates the conclusion.
In principle, the vesicles fragmented before or in a pore
could fuse back. The probability for this increases with
vesicle concentration, but probably did not affect the out-
come of our experiments. If it did, the pore size and flux
dependences illustrated in Figs. 3 and 4 should be different.
They should show discrete steps indicative of fusion or at
least should yield a detectable proportion of anomalously
large vesicles.
We estimated that the average width of pathways through
the skin is 20–30 nm [32]. A different experimental method
used; by other authors; yielded a similar value of 40 nm
[14]. This is why we chose the pores in the skin surrogate
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used in this study to have such diameter. The choice
permitted us to assess directly vesicle diameter changes in
the biologically relevant barriers for highly deformable
mixed lipid vesicles and for conventional liposomes.
With the former kind of vesicles we observed only insig-
nificant changes in lipid aggregate size when trans-barrier
flux was similar to the rate of material flow through the skin.
Even in the case of much higher suspension flux—and thus of
very large shear- and turbulence-stress on a vesicle—the final
size of ultradeformable vesicles was 3–6-fold greater than the
nominal diameter of pores in a barrier. In contrast, liposomes
were found to break down during trans-barrier passages when
pores were at least two times smaller than the average vesicle
diameter [15]; the proviso was that such lipid vesicles were
pushed into pores with a pressure of at least one order of
magnitude greater than in the tests with ultradeformable
vesicles. This is consistent with the previous findings for
liposomes by other authors [23–27]. The deviant behaviour
of ultradeformable vesicles and liposomes thus provides a
compelling evidence for the unique capability of the vesicles
with a highly flexible bilayer to move through a semi-
permeable barrier as intact, but dynamic, entities.
The high value of fluorescence distribution correlation
factor (Fig. 5) and the persistence of the central peak in the
two-dimensional correlation function for both labels tested
(Fig. 6) have the same meaning. They jointly support the
conclusion that chemical composition of the tested lipid
vesicles, as reflected in the distribution of different labels in
the skin, does not change appreciably during barrier passage.
In case of significant fragmentation, which exposes bilayer
edges with a different affinity for the two labels tested, such a
change should be observed, however. It is not possible to
perform a similar experiment with liposomes, since such
vesicles do not penetrate the skin to an appreciable depth [15].
The outcome of vesicle size determination by the size-
exclusion chromatography done before and after the skin
penetration complements aforesaid findings. It furthermore
extends the claim to physical (size) stability, that was
demonstrated directly in experiments with the skin surro-
gate. Our size chromatography results do not exclude the
possibility that some vesicles may have changed their size;
in fact, one would expect this to happen in the bloodstream.
Our results do show, however, that at least some lipid
aggregates must have reached the circulation as relatively
large entities, that is, intact.
We previously reported that radiolabelled phospholipids,
incorporated into ultradeformable vesicles, are transported
across the skin and reach systemic blood circulation via the
lymph in appreciable quantity [15]. In principle, this could
happen in the form of monomers/small fragments or of the
preserved, more or less ‘intact’ vesicles. If the former
scenario were true, one would expect lipids partitioning
into lipoproteins in the serum and their circulation in the
body. In the other extreme, the vesicle-derived material,
which reaches the blood in the form of vesicles, should
accumulate in the liver, as this organ is known to eliminate
particulates from the body. This is seen, for example, after
subcutaneous injections of conventional liposomes smaller
than approximately 120 nm [46]; approximately 30% of the
value achieved by an intravenous injection of such vesicles
is detected in the liver after corresponding s.c. injection. An
application of the radioactively labelled TransfersomesR on
the skin leads to a similar biodistribution. Dependent on the
applied dose, 5–30% of the epicutaneously administered
label from the ultradeformable vesicles is found in the liver
[32]. This also supports the view that TransfersomesR cross
the skin barrier as vesicles rather than as bilayer fragments.
Biodistribution measurements can only give an indica-
tion of aggregate size after the skin crossing. To get a more
quantitative picture, we separated fluorescent entities in the
sera of the mice treated epicutaneously with a labelled
vesicle suspension. This was done mainly with the size-
exclusion chromatography, which is well established for the
purpose [13], using epicutaneously Texas Red-DHPE
labelled ultradeformable vesicles on the skin. Fluorescence
elution profiles and refractive index traces were found to be
similar to those measured with the serum blanks spiked with
the original vesicle suspension (see Fig. 7). Fluorescence
activated cell sorter pictures obtained with the correspond-
ing samples were also undistinguishable (not shown). This
proves that aggregate size has not changed detectably during
the skin crossing.
In summary, we investigated the transport of various
aggregates in the form of vesicles through a barrier with
pores much smaller than the average vesicle diameter. We
detected great disparity in the behaviour of highly deformable
and conventional lipid vesicles. Most importantly, the former
kind of vesicles can cross semi-permeable barriers essentially
intact, whereas the latter type of lipid aggregates either cloggs
or breaks at the barrier. The conditions for the former
phenomenon are high lipid bilayer flexibility and permeabil-
ity and minimum tearing stress on the vesicles. Similar
conclusions are made for the artificial semi-permeable bar-
riers and for the skin, which is a premier biological boundary.
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